Exact Sciences Corp.(Nasdaq: EXAS) 35.0% HIGHER; announced that the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Determination (NCD) for Cologuard, making it the first and only Food and Drug Administration (FDA) approved stool DNA test for the detection of colorectal cancer and precancer covered by Medicare. Coverage will go into effect immediately. Exact Sciences is still awaiting a preliminary pricing determination from CMS.
Procera Networks (Nasdaq: PKT) 33.7% LOWER; reported preliminary revenue, bookings and gross margin rate results for the